IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer
Sponsor: Hokkaido Gastrointestinal Cancer Study Group
Suspended
Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.
Listed as NCT00316745, this PHASE3 trial focuses on Metastatic Colorectal Cancer and remains suspended. Sponsored by Hokkaido Gastrointestinal Cancer Study Group, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Suspended PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Suspended PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Suspended PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Suspended PHASE3
-
May 2018 — Jun 2018 [monthly]
Suspended PHASE3
-
Aug 2017 — May 2018 [monthly]
Suspended PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Suspended PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hokkaido Gastrointestinal Cancer Study Group
- Hokkaido University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .